Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$55.99
$63.50
$11.52B1.152.03 million shsN/A
CureVac N.V. stock logo
CVAC
CureVac
$5.43
+0.9%
$4.24
$2.37
$5.72
$1.21B2.49813,427 shs992,366 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$211.09
$207.95
$170.00
$292.80
$13.95B0.92240 shsN/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
$131.25
+1.2%
$134.18
$118.05
$200.56
$16.96B0.961,102 shs1,173 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+12.89%
CureVac N.V. stock logo
CVAC
CureVac
0.00%-1.10%+18.76%+94.22%+58.24%
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00%0.00%+1.61%+11.22%-14.01%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%0.00%
Merck KGaA stock logo
MKGAF
Merck KGaA
0.00%+4.25%-1.30%-7.74%-22.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalent, Inc. stock logo
CTLT
Catalent
1.0587 of 5 stars
1.00.00.04.60.00.01.9
CureVac N.V. stock logo
CVAC
CureVac
4.666 of 5 stars
4.15.00.04.81.70.01.3
Genmab A/S stock logo
GNMSF
Genmab A/S
0.3115 of 5 stars
0.03.00.00.00.00.01.3
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
1.1989 of 5 stars
0.00.00.03.20.61.71.9
Merck KGaA stock logo
MKGAF
Merck KGaA
1.3503 of 5 stars
0.01.00.00.02.40.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalent, Inc. stock logo
CTLT
Catalent
2.00
Hold$63.500.03% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8325.84% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00
N/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest HZNP, CVAC, MKGAF, GNMSF, and CTLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00 ➝ $5.50
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/28/2025
CureVac N.V. stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
4/30/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.10$0.88 per share6.16$3.36 per share1.62
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.47$15.19 per share13.90$80.53 per share2.62
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Merck KGaA stock logo
MKGAF
Merck KGaA
$22.72B0.75$39.53 per share3.32$212.00 per share0.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.925.90N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6311.97N/A35.11%19.23%15.44%8/7/2025 (Estimated)
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
$3.06B$6.8120.0412.44N/A12.60%10.17%5.74%8/7/2025 (Estimated)

Latest HZNP, CVAC, MKGAF, GNMSF, and CTLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
4/10/2025Q4 2024
CureVac N.V. stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
CureVac N.V. stock logo
CVAC
CureVac
0.05
7.65
7.64
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.34
5.32
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Merck KGaA stock logo
MKGAF
Merck KGaA
0.27
1.31
0.84

Institutional Ownership

CompanyInstitutional Ownership
Catalent, Inc. stock logo
CTLT
Catalent
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Merck KGaA stock logo
MKGAF
Merck KGaA
0.10%

Insider Ownership

CompanyInsider Ownership
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
CureVac N.V. stock logo
CVAC
CureVac
N/A
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Merck KGaA stock logo
MKGAF
Merck KGaA
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 millionN/AOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.07 million65.06 millionNot Optionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Merck KGaA stock logo
MKGAF
Merck KGaA
62,908129.24 millionN/ANot Optionable

Recent News About These Companies

Merck KGaA celebrates 350 years of innovation
Merck KGaA (MKGAF) Q1 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.43 +0.05 (+0.93%)
As of 04:00 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$211.09 0.00 (0.00%)
As of 06/27/2025

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Horizon Therapeutics Public stock logo

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKGAF

$131.25 +1.51 (+1.16%)
As of 03:54 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.